These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 7980648)

  • 1. Subcellular distribution of the alpha and beta topoisomerase II-DNA complexes stabilized by VM-26.
    Danks MK; Qiu J; Catapano CV; Schmidt CA; Beck WT; Fernandes DJ
    Biochem Pharmacol; 1994 Nov; 48(9):1785-95. PubMed ID: 7980648
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DNA topoisomerase II isozymes involved in anticancer drug action and resistance.
    Fernandes DJ; Qiu J; Catapano CV
    Adv Enzyme Regul; 1995; 35():265-81. PubMed ID: 7572348
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Decreased nuclear matrix DNA topoisomerase II in human leukemia cells resistant to VM-26 and m-AMSA.
    Fernandes DJ; Danks MK; Beck WT
    Biochemistry; 1990 May; 29(17):4235-41. PubMed ID: 2163274
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DNA topoisomerase II expression, stability, and phosphorylation in two VM-26-resistant human leukemic CEM sublines.
    Chen M; Beck WT
    Oncol Res; 1995; 7(2):103-11. PubMed ID: 7579726
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Formation of topoisomerase II alpha complexes with nascent DNA is related to VM-26-induced cytotoxicity.
    Qiu J; Catapano CV; Fernandes DJ
    Biochemistry; 1996 Dec; 35(50):16354-60. PubMed ID: 8973211
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Topoisomerase II cleavable complex formation within DNA loop domains.
    Lambert JM; Fernandes DJ
    Biochem Pharmacol; 2000 Jul; 60(1):101-9. PubMed ID: 10807951
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DNA topoisomerase II immunostaining in human leukemia and rhabdomyosarcoma cell lines and their responses to topoisomerase II inhibitors.
    Wolverton JS; Danks MK; Granzen B; Beck WT
    Cancer Res; 1992 Aug; 52(15):4248-53. PubMed ID: 1322239
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Topoisomerase II as a target of VM-26 and 4'-(9-acridinylamino)methanesulfon-m-aniside in atypical multidrug resistant human small cell lung carcinoma cells.
    de Jong S; Kooistra AJ; de Vries EG; Mulder NH; Zijlstra JG
    Cancer Res; 1993 Mar; 53(5):1064-71. PubMed ID: 8382551
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Teniposide-resistant CEM cells, which express mutant DNA topoisomerase II alpha, when treated with non-complex-stabilizing inhibitors of the enzyme, display no cross-resistance and reveal aberrant functions of the mutant enzyme.
    Chen M; Beck WT
    Cancer Res; 1993 Dec; 53(24):5946-53. PubMed ID: 8261408
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased ATP requirement for activity of and complex formation by DNA topoisomerase II from human leukemic CCRF-CEM cells selected for resistance to teniposide.
    Danks MK; Schmidt CA; Deneka DA; Beck WT
    Cancer Commun; 1989; 1(2):101-9. PubMed ID: 2561733
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single-strand conformational polymorphism analysis of the M(r) 170,000 isozyme of DNA topoisomerase II in human tumor cells.
    Danks MK; Warmoth MR; Friche E; Granzen B; Bugg BY; Harker WG; Zwelling LA; Futscher BW; Suttle DP; Beck WT
    Cancer Res; 1993 Mar; 53(6):1373-9. PubMed ID: 8383009
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Arrest of replication fork progression at sites of topoisomerase II-mediated DNA cleavage in human leukemia CEM cells incubated with VM-26.
    Catapano CV; Carbone GM; Pisani F; Qiu J; Fernandes DJ
    Biochemistry; 1997 May; 36(19):5739-48. PubMed ID: 9153414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differences between drug-sensitive and -resistant human leukemic CEM cells in c-jun expression, AP-1 DNA-binding activity, and formation of Jun/Fos family dimers, and their association with internucleosomal DNA ladders after treatment with VM-26.
    Kim R; Beck WT
    Cancer Res; 1994 Sep; 54(18):4958-66. PubMed ID: 8069863
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potentiation by novobiocin of the cytotoxic activity of etoposide (VP-16) and teniposide (VM-26).
    Rappa G; Lorico A; Sartorelli AC
    Int J Cancer; 1992 Jul; 51(5):780-7. PubMed ID: 1377186
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A drug-resistant variant of topoisomerase II alpha in human HL-60 cells exhibits alterations in catalytic pH optimum, DNA binding and sub-nuclear distribution.
    Boege F; Kjeldsen E; Gieseler F; Alsner J; Biersack H
    Eur J Biochem; 1993 Dec; 218(2):575-84. PubMed ID: 8269948
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of an amsacrine-resistant line of human leukemia cells. Evidence for a drug-resistant form of topoisomerase II.
    Zwelling LA; Hinds M; Chan D; Mayes J; Sie KL; Parker E; Silberman L; Radcliffe A; Beran M; Blick M
    J Biol Chem; 1989 Oct; 264(28):16411-20. PubMed ID: 2550442
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alterations in the topoisomerase II alpha gene, messenger RNA, and subcellular protein distribution as well as reduced expression of the DNA topoisomerase II beta enzyme in a mitoxantrone-resistant HL-60 human leukemia cell line.
    Harker WG; Slade DL; Parr RL; Feldhoff PW; Sullivan DM; Holguin MH
    Cancer Res; 1995 Apr; 55(8):1707-16. PubMed ID: 7712479
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic characterization of the multidrug-resistant phenotype of VM-26-resistant human leukemic cells.
    Wolverton JS; Danks MK; Schmidt CA; Beck WT
    Cancer Res; 1989 May; 49(9):2422-6. PubMed ID: 2539902
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of antileukemia agents on nuclear matrix-bound DNA replication in CCRF-CEM leukemia cells.
    Fernandes DJ; Smith-Nanni C; Paff MT; Neff TA
    Cancer Res; 1988 Apr; 48(7):1850-5. PubMed ID: 3349463
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure-activity studies of amsacrine analogs in drug resistant human leukemia cell lines expressing either altered DNA topoisomerase II or P-glycoprotein.
    Granzen B; Graves DE; Baguley BC; Danks MK; Beck WT
    Oncol Res; 1992; 4(11-12):489-96. PubMed ID: 1363724
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.